Literature DB >> 7102536

Treatment of angina pectoris with pindolol: the significance of intrinsic sympathomimetic activity of beta blockers.

J B Kostis, W Frishman, M H Hosler, N L Thorsen, L Gonasun, J Weinstein.   

Abstract

Although all beta blockers have been found to be effective in the symptomatic relief of angina pectoris, the importance of intrinsic sympathomimetic activity (ISA) has not been studied extensively. In a randomized, double-blind study, we administered equipotent doses of propranolol (10, 20, and 40 mg four times a day) and pindolol (2.5, 5, and 10 mg four times a day), a beta blocker with significant ISA, to 52 patients with angina. Both agents were found to be effective in the treatment of angina. At peak dose, propranolol reduced the number of angina attacks per 2 weeks from 29.29 +/- 4.79 to 18.0 +/- 4.4 (p = 0.021) (a 39% reduction) and increased the exercise tolerance on the treadmill from 7.55 +/- 0.67 METS to 9.36 +/- 0.58 (p = 0.002). Pindolol decreased the number of anginal attacks per 2 weeks from 16.48 +/- 2.63 to 8.65 +/- 2.46 (p = 0.0027) (a 48% reduction) and increased exercise tolerance from 7.95 +/- 0.56 METS to 9.40 +/- 0.57 (p = 0.0245). At the end of the maximum tolerated exercise, propranolol decreased the heart rate from 110.00 +/- 3.41 to 99.71 +/- 3.74 (p = 0.0015). Pindolol also decreased the heart rate at the maximum tolerated exercise from 113.59 +/- 3.24 to 108.12 +/- 3.16 (p = 0.0102). At rest, however, propranolol induced a more pronounced (p = 0.0066) decrease in heart rate (from 69.00 +/- 1.85 to 61.50 +/- 1.99; p = 0.0018), whereas pindolol did not significantly affect the resting heart rate (65.37 +/- 1.47 to 65.5 +/- 1.44; p = 0.9392). In addition propranolol decreased echocardiographically determined ejection fraction from 0.57 +/- 0.02 to 0.15 +/- 0.01 (p = 0.04) and increased the left ventricular end-diastolic volume from 71.8 +/- 3.2 to 92.2 +/- 1.9 ml (p = 0.003), whereas pindolol did not affect the ejection fraction and caused a less pronounced (p = 0.03) increase in end-diastolic volume (from 70.8 +/- 1.8 to 80.2 +/- 2.8; p = 0.02). The data indicate that both propranolol and pindolol are effective in the treatment of angina pectoris and that pindolol decreases the resting heart rate and ejection fraction and increases the left ventricular end-diastolic volume to a lesser extent than propranolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7102536     DOI: 10.1016/0002-8703(82)90146-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

2.  Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.

Authors:  L Barrios; J Geboers; J H Piessens; H de Geest
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  The influence of beta-adrenoceptor blockers with and without intrinsic sympathomimetic activity on heart rate, arrhythmias and ST-T segments, using ambulatory electrocardiography.

Authors:  R J Northcote; D Ballantyne
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

4.  Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol.

Authors:  A A Quyyumi; C Wright; L Mockus; K M Fox
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-13

5.  The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris.

Authors:  D L Johnston; D E Manyari; W J Kostuk
Journal:  Can Med Assoc J       Date:  1984-06-01       Impact factor: 8.262

6.  Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs.

Authors:  M Boucher; P Duchêne-Marullaz; J L Moundanga
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.